ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Incidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer.EClinicalMedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe combination of dabrafenib and trametinib has been used to treat a variety of cancers featuring BRAF mutations. The most common adverse effect is pyrexia syndrome. We aimed to determine the incidence of pyrexia syndrome and severe/complicated pyrexia syndrome and investigate outcomes associated with pyrexia syndrome as well as pyrexia management.
methodsIn this retrospective cohort study, individuals who received dabrafenib and trametinib from 2015 to 2022 at a large academic medical center were identified. Chart review was performed to determine if patients developed pyrexia syndrome, the severity of pyrexia syndrome, time of onset of pyrexia, time on treatment, how pyrexia was managed, and why treatment was discontinued.
results88 patients were included in the final analysis. 34 patients (38.6%) developed pyrexia syndrome and 14 patients (15.9%) developed severe/complicated pyrexia syndrome. Most patients who developed pyrexia syndrome did so in their first month of treatment. Patients who developed pyrexia syndrome were more likely to discontinue treatment due to an adverse event than patients who did not (32.3% vs 22.2%). Patients who developed pyrexia syndrome spent a longer mean period on treatment (16.9 months) than patients who did not (9.0 months). Pyrexia syndrome was managed with dose modifications and interruptions and several agents including steroids, antipyretics, and colchicine.
conclusionPyrexia syndrome is a common adverse event in patients on dabrafenib and trametinib. Patients who develop pyrexia syndrome unexpectedly stayed on treatment longer in our cohort, highlighting the importance of early recognition and supportive management to maintain patients on therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.